Fig. 3From: Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trialCMA alters plasma metabolite levels. a Differences in the plasma levels of individual CMA, including serine, carnitine, cysteine and nicotinamide on days 0 and 84. b–d Plasma levels of amino acids, lipids and other metabolites that were significantly different between day 84 and day 0 in the CMA and placebo groups. Adjusted P < 0.05. Heatmap shows log2FC values of metabolites between day 84 and day 0. Asterisks indicate statistical significance based on paired Student’s t-test. Adjusted P < 0.05. Log2FC: log2(fold change)Back to article page